The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Zalevsky Jonathan since 2019.
This trader's CIK number is 1789857.
At the time of last reporting, Zalevsky Jonathan was the Chief R&D Officer of Nektar Therapeutics. (stock ticker symbol NKTR).
Also see all insider trading activities at Nektar Therapeutics.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NKTR | 0 | $0 | 22,222 | $51,455 | 0 | $0 |
| 2024 | NKTR | 0 | $0 | 82,135 | $83,698 | 0 | $0 |
| 2023 | NKTR | 0 | $0 | 39,624 | $50,795 | 0 | $0 |
| 2022 | NKTR | 0 | $0 | 56,605 | $303,411 | 0 | $0 |
| 2021 | NKTR | 0 | $0 | 83,783 | $1,489,966 | 0 | $0 |
| 2020 | NKTR | 0 | $0 | 81,530 | $1,494,716 | 0 | $0 |
| 2019 | NKTR | 0 | $0 | 3,960 | $71,161 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | NKTR | Sale | 485 | 30.10 | 14,598 |
| 2025-08-19 | NKTR | Sale | 725 | 26.59 | 19,277 |
| 2025-05-19 | NKTR | Sale | 10,712 | .67 | 7,177 |
| 2025-02-19 | NKTR | Sale | 10,300 | 1.01 | 10,403 |
| 2024-12-19 | NKTR | Sale | 51,115 | .94 | 48,048 |
| 2024-11-19 | NKTR | Sale | 7,785 | 1.01 | 7,862 |
| 2024-08-19 | NKTR | Sale | 6,866 | 1.28 | 8,788 |
| 2024-05-17 | NKTR | Sale | 7,355 | 1.75 | 12,871 |
| 2024-02-20 | NKTR | Sale | 9,014 | .68 | 6,129 |
| 2023-11-17 | NKTR | Sale | 9,646 | .49 | 4,726 |
| 2023-08-16 | NKTR | Sale | 9,703 | .78 | 7,568 |
| 2023-05-16 | NKTR | Sale | 9,791 | .72 | 7,049 |
| 2023-02-16 | NKTR | Sale | 10,484 | 3.00 | 31,452 |
| 2022-11-16 | NKTR | Sale | 13,460 | 3.57 | 48,052 |
| 2022-08-16 | NKTR | Sale | 10,560 | 4.76 | 50,265 |
| 2022-05-16 | NKTR | Sale | 21,673 | 3.95 | 85,608 |
| 2022-02-16 | NKTR | Sale | 10,912 | 10.95 | 119,486 |
| 2021-11-16 | NKTR | Sale | 20,869 | 13.16 | 274,636 |
| 2021-08-16 | NKTR | Sale | 7,662 | 13.83 | 105,965 |
| 2021-05-17 | NKTR | Sale | 31,111 | 18.30 | 569,331 |
| 2021-02-16 | NKTR | Sale | 24,141 | 22.37 | 540,034 |
| 2020-11-23 | NKTR | Sale | 16,380 | 16.40 | 268,632 |
| 2020-11-16 | NKTR | Sale | 29,618 | 16.93 | 501,432 |
| 2020-08-17 | NKTR | Sale | 26,200 | 19.67 | 515,354 |
| 2020-05-18 | NKTR | Sale | 4,558 | 22.51 | 102,600 |
| 2020-02-18 | NKTR | Sale | 4,774 | 22.35 | 106,698 |
| 2019-11-18 | NKTR | Sale | 3,960 | 17.97 | 71,161 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Zalevsky Jonathan (Chief R&D Officer of Nektar Therapeutics at the time of this reporting) see the Securities and Exchange Commission (SEC) website.